Evidence map›Paper›PMID 42108281›Full record

ArticleNpj viruses2026

A robust cell-based infection model for Rhinovirus C research and antiviral drug discovery.

Heyrhyoung Lyoo, Yeranddy A Alpizar, Céline Sablon, Toon Röpke, Jasmine Paulissen, Madina Rasulova, Nathalie Thys, Chang-Soo Yun, Nam-Chul Cho, Kai Dallmeier and 4 more

Abstract read
In one paragraph

Article in Npj viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Heyrhyoung LyooTranslational Platform for Virus, Vaccine and Cancer Research (TPVC), Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Yeranddy A AlpizarLaboratory of Molecular Vaccinology & Vaccine Discovery (MVVD), Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Céline SablonTranslational Platform for Virus, Vaccine and Cancer Research (TPVC), Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Toon RöpkeTranslational Platform for Virus, Vaccine and Cancer Research (TPVC), Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Jasmine PaulissenTranslational Platform for Virus, Vaccine and Cancer Research (TPVC), Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Madina RasulovaTranslational Platform for Virus, Vaccine and Cancer Research (TPVC), Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Nathalie ThysTranslational Platform for Virus, Vaccine and Cancer Research (TPVC), Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Chang-Soo YunTherapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Nam-Chul ChoDrug Information Platform Center, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Kai DallmeierLaboratory of Molecular Vaccinology & Vaccine Discovery (MVVD), Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Pieter LeyssenCaps-It, Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Soo-Bong HanTherapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Johan NeytsLaboratory of Virology & Antiviral Research (AntiVir), Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. johan.neyts@kuleuven.be.
Hendrik Jan ThibautTranslational Platform for Virus, Vaccine and Cancer Research (TPVC), Virology, Antiviral Drug and Vaccine Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. hendrikjan.thibaut@kuleuven.be.

Funding

National Research Foundation of Korea RS-2024-00432287
6 · The paper itself

Abstract

Rhinoviruses (RV) comprise three species, RV-A, RV-B, and RV-C, with approximately 170 types. RV-C is associated with severe respiratory illness, particularly in children and individuals with asthma or chronic obstructive pulmonary disease, underscoring the need for effective antiviral strategies. Progress in RV-C research and drug discovery has been limited by the lack of robust, scalable cell-based infection models that recapitulate the complete RV-C replication cycle. Here, we describe a high-content imaging (HCI)-based high-throughput infection system for RV-C. Rather than relying solely on receptor overexpression, we used a genetically stable fluorescent reporter virus (RV-C15a-mGL) to screen ~300 monoclonal cell lines expressing the RV-C receptor variant CDHR3-Tyr529. This approach identified a clone that efficiently supports RV-C replication and revealed that productive infection depends on determinants beyond receptor abundance alone. Using this clone, we established and validated a robust, scalable screening platform with Z' > 0.75 in both 96- and 384-well formats. The system was readily adapted to additional RV-C types (C11 and C41), as well as RV-A and RV-B. A pilot screen of approximately 10,000 small molecules identified both known and novel RV-C inhibitors, supporting the utility of this platform for antiviral discovery and for advancing the study of RV-C biology.

Identifiers

PMID42108281
PMCPMC13381550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.